|
Racotumomab-alum for recurrent platimun-sensitive epithelial ovarian cancer |
08/07/2015 |
CIM |
|
Racotumomab-alum cancer vaccine for solid tumors in pediatric patients |
15/12/2015 |
CIM |
|
CIMAbior® in CD20-positive B-cell Non-Hodgkin Lymphoma |
05/09/2017 |
CIM |
|
Vaxira as adjuvant treatment for non-small cell lung cancer |
15/12/2015 |
CIM |
|
Dose scale-up and cohort expansion with the therapeutic mAb 14F7 |
04/12/2015 |
CIM |
|
NeuroEPO in patients with Mild-Moderate Alzheimer's disease |
01/02/2017 |
CIM |
|
Phase I/II trial with the mutein no alfa of IL-2 |
03/02/2017 |
CIM |
|
Combined NGcGM3/VSSP and Nimotuzumab in advanced non-small cell lung cancer (NSCLC) |
30/04/2018 |
CIM |
|
NGcGM3/VSSP in patients with metastatic hormone-receptor positive and HER2 negative breast cancer |
28/11/2016 |
CIM |
|
Nimotuzumab cold kit for the immunodiagnosis of solid tumors |
05/10/2018 |
CIM |
|
CIMAvax-EGF® in metastatic asymptomatic or mildly symptomatic Castration Resistant Prostate Cancer patients. Phase II-III Clinical Trial |
17/10/2018 |
CIM |
|
VSSP in metastasic renal cell carcinoma |
08/08/2018 |
CIM |
|
Racotumomab vaccine- Lung Cancer- Adults-predictors of response - Exploratory |
09/07/2018 |
CIM |
|
Nimotuzumab in Non-Small Cell Lung Cancer (NSCLC) of inoperable stage III epidermoid histology, concomitant with Chemo and Radiotherapy (CRT) |
28/12/2018 |
CIM |
|
CIMAvax-EGF in patients at high risk of lung cancer |
22/10/2020 |
CIM |
|
Safety and efficacy of VAXIRA® in advanced NSCLC patients not progressing after first line chemotherapy. Phase III. |
01/10/2020 |
CIM |
|
NeuroEPO-Ataxia-Adults-Phase III |
19/11/2020 |
CIM |
|
Phyisician Led CIMAvax-EGF lung biomarkers |
11/03/2021 |
CIM |
|
Itolizumab Safety and Efficacy Study in Covid 19 |
26/03/2021 |
CIM |
|
CIMAvax-EGF®-post-COVID19 convalescent with respiratory disorders-adults-Phase II (CORVAXCIM) |
18/06/2021 |
CIM |
